ReviewRSC advances2026
Recent advances in the biosensing platforms for sepsis diagnosis.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Localized surface plasmon resonance-based point-of-care testing for pediatric sepsis.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is one of the major causes of mortality and organ losses due to the infections caused before or after hospitalization. According to the World Health Organization (WHO), 11 million people died from sepsis in 2020, which accounted for 20% of all deaths reported worldwide in the same year. This was out of an estimated 48.9 million cases of sepsis that year. Thus, the timely detection and treatment of sepsis are crucial for saving lives and organs of patients. There has been a continuous effort to identify and quantify the microbial load as well as ensure detection at an early stage of infection for ensuring the right treatment. There are various methods for identifying blood-based pathogens, and each of them has their own sensitivity and limit of detection (LOD). Identification by electrochemical and optical methods is unique in terms of their need and condition to be used. In remote and resource-deprived locations, paper-based, microfluidic, electrochemical or easy-to-use devices based on less-energy-intensive methods are more useful. In this work, we present the recent developments and challenges in the field of sepsis-related biosensors. The developments in neonatal-related sepsis biomarkers and sensors, the pathophysiology of sepsis, and the six categories of sepsis biosensors, with the relevant biomarkers, limits of detection (LOD), ease of extraction from bodily/interstitial fluids or analytes and their sensing mechanisms are discussed. The sensing mechanism plays a crucial role in deciding the reliability and durability of such sensors. The challenges in finding biomarkers directly from blood and preserving them while maintaining the integrity and viability for detection are discussed here. With the advent of the new era of artificial intelligence and machine learning, various diagnostic processes and techniques based on these technologies are developed, which are also discussed. This study presents a comprehensive analysis of different sensing techniques, with a particular focus on their sensitivity and limit of detection (LOD), and new mechanisms to simplify the process of pathogen detection with minimal processing time and process innovation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.